Cohance Lifesciences Limited vs Glenmark Pharmaceuticals Limited
Last updated: 5 November 2026
Cohance Lifesciences vs. Glenmark Pharmaceuticals: A MoneyDock Comparison
In the dynamic Indian pharmaceutical sector, Cohance Lifesciences Limited and Glenmark Pharmaceuticals Limited stand out as prominent players, each with their unique market positions and financial trajectories. Both companies are engaged in the development, manufacturing, and marketing of pharmaceutical products, catering to a diverse range of therapeutic areas. This comparison aims to provide MoneyDock readers with a clear, data-driven analysis of these two entities, using key financial metrics to help investors make informed decisions. While Glenmark is a well-established name with a global footprint, Cohance Lifesciences, though newer to public scrutiny, presents an intriguing alternative. Understanding their performance across various parameters is crucial for discerning investors looking to navigate the Indian pharma landscape.
Key Financial Metrics Comparison
| Metric | Cohance Lifesciences Limited (COHANCE.NS) | Glenmark Pharmaceuticals Limited (GLENMARK.NS) |
|---|---|---|
| Current Price | ₹449.00 | ₹2481.80 |
| 52-Week High | ₹537.35 | ₹2515.00 |
| 52-Week Low | ₹279.90 | ₹1920.40 |
| 1-Year Return | -16.44% | 23.44% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When we delve into the numbers, Glenmark Pharmaceuticals Limited clearly emerges as the stronger performer in terms of returns and market positioning. With a 1-year return of 23.44%, Glenmark has delivered substantial positive growth for its shareholders, significantly outperforming Cohance Lifesciences Limited, which recorded a negative return of -16.44% over the same period. This stark contrast in returns highlights Glenmark's current momentum and investor confidence compared to Cohance.
In terms of valuation, both companies currently have a 'N/A' for Trailing P/E and Market Cap, which limits a direct valuation comparison based on these common metrics. However, considering the current price, Glenmark trades at a much higher value of ₹2481.80 per share compared to Cohance's ₹449.00. This higher share price for Glenmark, coupled with its positive returns, suggests a more premium valuation by the market, likely reflecting its established position and better recent performance.
Regarding stability, Glenmark's 52-week price range from ₹1920.40 to ₹2515.00 shows a stock that is trading very close to its 52-week high, indicating strong upward momentum and investor bullishness. Its current price of ₹2481.80 is just slightly below its peak, suggesting a relatively stable upward trend. Cohance, on the other hand, with a 52-week range of ₹279.90 to ₹537.35 and a current price of ₹449.00, is trading significantly below its 52-week high but also well above its low. The negative 1-year return suggests a period of recent volatility and downward pressure for Cohance, indicating less short-term stability compared to Glenmark.
Overall, Glenmark Pharmaceuticals appears to be the more stable and higher-performing stock based on the provided metrics, particularly in terms of recent price action and returns. Cohance, while trading above its 52-week low, has experienced a challenging year, suggesting a higher risk profile for investors looking at short-to-medium term gains.
MoneyDock Verdict
For Aggressive Investors: Glenmark Pharmaceuticals Limited looks like the more appealing option. Its strong positive 1-year return of 23.44% and current price near its 52-week high suggest robust market confidence and growth potential. Aggressive investors might find its momentum attractive, despite the higher per-share price.
For Conservative Investors: Given the available data, neither stock presents a clear conservative choice without more detailed financial statements like P/E and Market Cap. However, Cohance's negative 1-year return indicates higher risk in the short term. Conservative investors would likely prefer to wait for more stable performance and clear valuation metrics for both companies.
For Long-term SIP Investors: Glenmark appears to be the stronger candidate. Its sustained positive returns over the past year indicate a business with positive trajectory, which is crucial for long-term wealth creation through Systematic Investment Plans (SIPs). Cohance, with its negative one-year return, might require a deeper dive into its turnaround strategy before being considered for a long-term SIP, as its current trend suggests a need for caution.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.